20-oxo-5β-pregnan-3α-yl 7-carboxyheptanoate | 1256911-30-4

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: 20-oxo-5β-pregnan-3α-yl 7-carboxyheptanoate
• 英文别名: 8-[[(3R,5R,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-8-oxooctanoic acid
• CAS: 1256911-30-4
• 化学式: C₂₉H₄₆O₅
• 分子量: 474.681
• InChiKey: HUCIJNJTHQQOKL-MOBAGVSDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  34
• 可旋转键数：
  10
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  80.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• STEROIDE ANIONIC COMPOUNDS, METHOD OF THEIR PRODUCTION, USAGE AND PHARMACEUTICAL PREPARATION INVOLVING THEM
  申请人：Chodounska Hana

  公开号：US20120071453A1

  公开（公告）日：2012-03-22

  A compound with general formula I for treatment of various diseases of the central nervous system, in treatment of neuropsychiatric disorders related to imbalance of glutamatergic neurotransmitter system, ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, PTSD and other diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addictions, multiple sclerosis, epilepsy and gliomas.

  一种通用化合物，用于治疗中枢神经系统的各种疾病，治疗与谷氨酸能神经递质系统失衡相关的神经精神障碍，中枢神经系统的缺血性损伤，神经退行性变化和中枢神经系统的疾病，情感障碍，抑郁症，创伤后应激障碍以及与压力、焦虑、精神分裂症和精神障碍、疼痛、成瘾、多发性硬化症、癫痫和胶质瘤相关的其他疾病。
• STEROID ANIONIC COMPOUNDS, METHOD FOR THEIR PRODUCTION, USE AND PHARMACEUTICAL PREPARATION CONTAINING THEM
  申请人：Ústav Organické Chemie A Biochemie Akademie Ved Ceské Republiky, v.v.i.

  公开号：EP3243829A1

  公开（公告）日：2017-11-15

  The presented invention applies to the compounds with general formula I, where R1 stands for a group of the general formula R3 OOC-R2- C (R4)-R5 -, where R2 stands for alkyl or alkenyl group with 1 to 18 carbon in a straight or a branching carbon chain, which may be substituted by one or more halogen atoms; R3represents either a hydrogen atom or a protecting group of carboxyl groups, preferably benzyl group; R4 represents oxygen atom, nitrogen atom or a sulfur atom bound by a double bond or R4 represents two hydrogen atoms; R5 represents any at least bivalent atom, preferably an oxygen atom, nitrogen, or carbon atom, except when R2 represents the group -(CH2)n- where n = 0-3 and simultaneously R3 represents a hydrogen atom and R4 and R5 represent an oxygen atom. The present invention also relates to the production process of the compounds with general formula I, where R1 stands for as mentioned previously, the compounds with general formula I for use in treatment of various diseases of central nervous system, in treatment of neuropsychiatric disorders related to imbalance of glutamatergic neurotransmitter system, ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, PTSD and other diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addictions, multiple sclerosis, epilepsy and gliomas. This invention further applies to the compounds with general formula I for use in the production of veterinary and human pharmaceutical preparations for use in treatment of above mentioned diseases as well as in production of substances used in experimental research, analytic chemistry, dietary supplements or cosmetic preparations.

  本发明适用于通式 I 的化合物，其中 R1 代表通式 R3 OOC-R2- C (R4)-R5 - 的基团，其中 R2 代表在直链或分支碳链中具有 1 至 18 个碳的烷基或烯基，可被一个或多个卤素原子取代；R3 代表氢原子或羧基保护基团，最好是苄基；R4代表氧原子、氮原子或通过双键结合的硫原子，或者R4代表两个氢原子；R5代表任何至少二价原子，最好是氧原子、氮原子或碳原子，除非R2代表基团-(CH2)n-，其中n＝0-3，同时R3代表氢原子，R4和R5代表氧原子。本发明还涉及通式 I（其中 R1 代表如前所述）化合物的生产工艺，通式 I 化合物用于治疗各种中枢神经系统疾病，治疗与谷氨酸能神经递质系统失衡有关的神经精神疾病、中枢神经系统缺血性损伤、中枢神经系统神经退行性变化和紊乱、情感障碍、抑郁症、创伤后应激障碍和其他与压力、焦虑、精神分裂症和精神病、疼痛、成瘾、多发性硬化症、癫痫和胶质瘤有关的疾病。 本发明还适用于通式 I 的化合物，用于生产治疗上述疾病的兽药和人用药制剂，以及生产用于实验研究、分析化学、膳食补充剂或化妆品制剂的物质。
• US8575376B2
  申请人：——

  公开号：US8575376B2

  公开（公告）日：2013-11-05